National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. (September 2021)
- Record Type:
- Journal Article
- Title:
- National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. (September 2021)
- Main Title:
- National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic
- Authors:
- Palmateer, N.E.
Dickson, E.
Furrie, E.
Godber, I.
Goldberg, D.J.
Gousias, P.
Jarvis, L.
Mathie, L.
Mavin, S.
McMenamin, J.
McNeilly, T.N.
Murcia, P.
Murray, J.
Reid, G.
Robertson, C.
Templeton, K.
von Wissmann, B.
Wallace, L.A.
Waugh, C.
McAuley, A. - Abstract:
- Abstract: Objectives: Studies that measure the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ('seroprevalence') are essential to understand population exposure to SARS-CoV-2 among symptomatic and asymptomatic individuals. We aimed to measure seroprevalence in the Scottish population over the course of the COVID-19 pandemic – from before the first recorded case in Scotland through to the second pandemic wave. Study design: The study design of this study is serial cross sectional. Methods: We tested 41, 477 residual samples retrieved from primary and antenatal care settings across Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (before rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in seroprevalence estimates and weekly SARS-CoV-2 notifications were compared. Results: Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the summer (range: 3%–5%) during a period of social restrictions, after which they increased concurrently with the second wave, reaching 9.6% (95% confidence interval [CI]: 8.4%–10.8%) in the week beginning 28th December in 2020. Seroprevalence rates were lower in rural vs. urban areas (adjustedAbstract: Objectives: Studies that measure the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ('seroprevalence') are essential to understand population exposure to SARS-CoV-2 among symptomatic and asymptomatic individuals. We aimed to measure seroprevalence in the Scottish population over the course of the COVID-19 pandemic – from before the first recorded case in Scotland through to the second pandemic wave. Study design: The study design of this study is serial cross sectional. Methods: We tested 41, 477 residual samples retrieved from primary and antenatal care settings across Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (before rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in seroprevalence estimates and weekly SARS-CoV-2 notifications were compared. Results: Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the summer (range: 3%–5%) during a period of social restrictions, after which they increased concurrently with the second wave, reaching 9.6% (95% confidence interval [CI]: 8.4%–10.8%) in the week beginning 28th December in 2020. Seroprevalence rates were lower in rural vs. urban areas (adjusted odds ratio [AOR]: 0.70, 95% CI: 0.61–0.79) and among individuals aged 20–39 years and 60 years and older (AOR: 0.74, 95% CI: 0.64–0.86; AOR: 0.80, 95% CI: 0.69–0.91, respectively) relative to those aged 0–19 years. Conclusions: After two waves of the COVID-19 pandemic, less than one in ten individuals in the Scottish population had antibodies to SARS-CoV-2. Seroprevalence may underestimate the true population exposure as a result of waning antibodies among individuals who were infected early in the first wave. … (more)
- Is Part Of:
- Public health. Volume 198(2021)
- Journal:
- Public health
- Issue:
- Volume 198(2021)
- Issue Display:
- Volume 198, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 198
- Issue:
- 2021
- Issue Sort Value:
- 2021-0198-2021-0000
- Page Start:
- 102
- Page End:
- 105
- Publication Date:
- 2021-09
- Subjects:
- SARS-CoV-2 -- COVID-19 -- Seroprevalence -- Antibodies -- Cross sectional
Public health -- Periodicals
Public health -- Periodicals
Electronic journals
362.1 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00333506 ↗
http://intl.elsevierhealth.com/journals/pubh/ ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00333506 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/00333506 ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/public-health ↗ - DOI:
- 10.1016/j.puhe.2021.07.006 ↗
- Languages:
- English
- ISSNs:
- 0033-3506
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6963.850000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19549.xml